胆酸
CYP8B1
法尼甾体X受体
结肠炎
生物
LGR5型
内科学
胆汁酸
癌症研究
干细胞
内分泌学
细胞生物学
核受体
生物化学
免疫学
医学
转录因子
癌症干细胞
基因
作者
Li Chen,Tingying Jiao,Weiwei Liu,Yuhong Luo,Jue Wang,Xiaozhen Guo,Tong Xiao,Zemin Lin,Chuying Sun,Kanglong Wang,Yifan He,Shouxin Zhang,Hualing Xu,Jiawen Wang,Jianping Zuo,Qiurong Ding,Shijun He,Frank J. Gonzalez,Cen Xie
出处
期刊:Cell Stem Cell
[Elsevier]
日期:2022-09-01
卷期号:29 (9): 1366-1381.e9
被引量:66
标识
DOI:10.1016/j.stem.2022.08.008
摘要
Although disrupted bile acid (BA) homeostasis is implicated in inflammatory bowel disease (IBD), the role of hepatic BA metabolism in the pathogenesis of colitis is poorly understood. Here, we found that cholic acid (CA) levels were increased in patients and mice. Cytochrome P450 8B1 (CYP8B1), which synthesizes CA, was induced in livers of colitic mice. CA-treated or liver Cyp8b1-overexpressing mice developed more severe colitis with compromised repair of the mucosal barrier, whereas Cyp8b1-knockout mice were resistant to colitis. Mechanistically, CA inhibited peroxisome proliferator-activated receptor alpha (PPARα), resulting in impeded fatty acid oxidation (FAO) and impaired Lgr5+ intestinal stem cell (ISC) renewal. A PPARα agonist restored FAO and improved Lgr5+ ISC function. Activation of the farnesoid X receptor (FXR) suppressed liver CYP8B1 expression and ameliorated colitis in mice. This study reveals a connection between the hepatic CYP8B1-CA axis and colitis via regulating intestinal epithelial regeneration, suggesting that BA-based strategies might be beneficial in IBD treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI